Drug intelligence / Profile preview

AS-S603

Development stage: Phase 1
Lead developer: Amyloid Solution
Modality: Small Molecules
Administration: Oral

Overview

AS-S603 is an orally administered small molecule drug developed by Amyloid Solution Co., Ltd. for the treatment of Alzheimer's disease. Its mechanism of action involves targeting and dissolving amyloid-beta (Aβ) and tau aggregates, which are key pathological features found in the extracellular and intracellular spaces of brain cells in Alzheimer's disease. The drug is currently being evaluated in a phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy adults and elderly individuals[1][3][2].

Other names: AS 603AS603AS-603

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on AS-S603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS-S603.

Explore the full profile